NIAID Funding News, November 6, 2024

November 6, 2024 NIAID Funding News Read this full edition online at https://www.niaid.nih.gov/grants-contracts/funding-news?edition=2024-11-06 Feature Articles  Long COVID and the RECOVER-TLC Initiative Long COVID's broad and varied effects on diverse populations demand new clinical approaches and fewer restrictions to inclusion and access to achieve breakthrough results. Opportunities and Resources Develop Therapeutic Treatments for Genital Herpes Through Novel Approaches NIAID seeks to capitalize on the robust herpes simplex virus basic research field and encourage more researchers to advance products into the development pipeline. NIAID Calls for Development of Alternative Human Models to Address Radiation-Induced Injuries Find support for early- to mid-stage research and development of extracorporeal systems that mimic human responses and testing of appropriate medical countermeasures to treat civilian populations. Administrative Supplements for Women's Health Research in U3 Populations Active grant awardees can receive support for in-scope research to reduce health inequalities among women who are understudied, underrepresented, or underreported in biomedical research. In The News Checking in on NIH's Efforts to Enhance Racial and Ethnic Equity NIH is committed to addressing structural racism that may exist within the biomedical and behavioral ecosystem through three primary domains—health disparities/minority health research, the internal NIH workforce, and the external biomedical and behavioral research workforce.  News Briefs and Worth Repeating Last Call to Answer the NIAID Funding News Survey Register Now for Small Business Entrepreneurship Boot Camp Double Dipping Could Lead to Payback Instruction for Labs Working with Synthetic Nucleic Acids Advice Corner Take Some Hints from Our New R01, K08 Sample Applications NIAID recently posted two R01 sample applications and one K08 sample application to serve as examples of outstanding grantsmanship and demonstrate a successful approach to presenting a research plan. Reader Questions "Am I more likely to receive a grant if my application's budget request is thrifty?" "Does NIAID monitor the visa status of foreign investigators at domestic institutions?" New Funding Opportunities RFA-AI-24-074, Combating Antibiotic-Resistant Bacteria Interdisciplinary Units (CARBIRUs) (P01, Clinical Trial Not Allowed) PAR-25-077, CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) Basic Research on Chemical Threats that Affect the Nervous System (R01, Clinical Trial Not Allowed) PAR-25-143, Dissemination and Implementation Research in Health (R21, Clinical Trial Optional) NOT-AI-24-082, Notice of Special Interest (NOSI): Establishing and Utilizing Pre-Clinical Animal Models to Study Post-TB Lung Disease Development PAR-25-144, Dissemination and Implementation Research in Health (R01, Clinical Trial Optional) NOT-OD-24-180, Notice of Special Interest (NOSI): Administrative Supplements to Support Extramural Collaborators for Notified Applicants for the Bench-to-Bedside and Back Program (BtB) (Clinical Trial Optional) PAR-25-122, Pilot Projects Investigating Understudied Proteins Associated with Rare Diseases (R03, Clinical Trial Not Allowed) NOT-OD-25-009, Notice of Special Interest (NOSI): Availability of Administrative Supplements for Childcare Costs for Ruth L. Kirschstein National Research Service Award (NRSA) Individual Fellows NOT-OD-25-015, Notice of Special Interest (NOSI): Administrative Supplement for Research and Capacity Building Efforts Related to Bioethical Issues (Admin Supp, Clinical Trial Optional) PAR-25-114, CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) Translational Exploratory/Developmental Research Projects (R21, Clinical Trial Not Allowed) RFA-AI-24-069, Centers for Accelerating Phage (Bacteriophage) Therapy to Combat ESKAPE Pathogens (CAPT-CEP) (P01, Clinical Trial Not Allowed) PA-25-212, Innovation Corps (I-Corps) at NIH Program for NIH and CDC Translational Research (Admin Supp, Clinical Trial NOT Allowed) RFP-NIAID-75N93024R00018, NIAID Clinical Products Center (CPC) Find other announcements at NIAID Opportunities and Announcements. Send suggestions or comments to deaweb@niaid.nih.gov. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. Your subscription may be removed if you do not open our emails for a six-month period.  This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to edwardlorilla1986.paxforex@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107